Insurance by BogdanovaThe Encyclopedia of Insurance and Risk Science

RESEARCH DOSSIER

Insurance Product Review Triggers and Withdrawal Governance

Abstract. Insurance product review is the institutional process by which a manufacturer tests the continued validity of the coverage, pricing, distribution and customer-outcome assumptions underlying an approved insurance proposition. Withdrawal governance determines how an insurer restricts further exposure, preserves existing contractual rights, addresses previous detriment and manages the consequences of leaving a product or market. This monograph examines the connection between scheduled and event-triggered reviews, quantitative and qualitative signals, independent evaluation, corrective repricing, sales suspension, customer remediation and the obligations of a closed portfolio. It compares European Union product oversight and governance, United Kingdom fair-value rules, Australian design and distribution obligations, Texas withdrawal procedures and the International Association of Insurance Supervisors' supervisory framework. The method combines comparative doctrinal analysis, critical evaluation of supervisory evidence and worked hypothetical monitoring examples. The central analytical finding is that a product review must distinguish the evidence needed to initiate inquiry from the evidence needed to select a remedy, while taking interim protective measures when delay may expose customers to material harm. The governance of exit is complete only when distribution decisions and continuing liabilities are addressed together. No independent empirical effect estimate or new regulatory doctrine is proposed.

Keywords: Insurance product governance; product review triggers; market conduct; target market; fair value; distribution suspension; product withdrawal; run-off; customer remediation; insurance supervision.

Introduction

An insurance product is a continuing relationship between an institution's promise to absorb or finance specified loss and the policyholder's payment, conduct and reliance on that promise. The point of sale establishes a contractual relationship, but the quality of the proposition becomes observable over time through renewals, claims, communications, exclusions, service performance and changes in the customer's need for protection. An approval decision made at launch is consequently a conclusion about a particular design, population and distribution arrangement under assumptions that can change.

A review trigger is an observation or event requiring reassessment under a product's governance arrangements. A scheduled review occurs at an established interval even if no identified anomaly has arisen. Event-triggered review responds to emerging information that makes the existing assessment potentially unreliable. Both mechanisms serve the same purpose: maintaining a defensible relationship among the contractual proposition, the intended population and actual outcomes.

Withdrawal means ending or materially restricting the future availability of a proposition. It may involve closing a channel, stopping new sales, declining future renewals where legally permissible, or leaving an insurance line or territory. These decisions differ from rescinding an individual contract, transferring a portfolio or entering resolution as an insurer. Each changes a different set of rights, risks and responsibilities. In this study withdrawal includes the organizational decisions surrounding product suspension and permanent exit; formal insurer resolution, specialized claims adjudication, portfolio transfer law and new-business underwriting are considered only at their interfaces with product governance.

The economic problem underlying review is that the benefits of insurance are contingent and heterogeneous. A contract with a low observed payout can provide valuable protection from rare catastrophic loss; conversely, a high payout ratio may coexist with inaccessible claims processes, unsuitable exclusions or inappropriate sales. The observed price of insurance also finances expenses, risk capital and the costs of obtaining and administering coverage. It is necessary to establish why experience diverges from the proposition rather than equating a single ratio with quality.

The legal problem is the allocation of duties across an insurer, intermediaries and other participants able to influence outcomes. Marano's (2021) organizational analysis of POG locates European product governance in internal business arrangements and their control. This interpretation helps explain why a committee's approval record alone is insufficient evidence of effective governance: the decision must be implemented in the operations that determine the product's actual customer experience.

The research asks three questions. Which measurable or qualitative events warrant review? How should harm, uncertainty and proportionality shape the remedy? What responsibilities persist after suspension or withdrawal? The comparative method selects official instruments with functionally distinct regulatory features and examines their operative provisions and public supervisory summaries. The cases illustrate institutional actions rather than identify their causal effects. Numerical examples are hypothetical and repeatable; no confidential insurer data, international prevalence estimate or general statistical threshold is inferred from them. The legal reference date is November 19, 2026; the analysis is bounded by the versions and materials identified in References, and local implementing rules and subsequent changes require separate verification in an actual transaction.

Product lifecycle and review obligations

The reviewed object

Product governance begins with the definition of the reviewed object. A policy form is essential but rarely sufficient. The customer may encounter multiple versions of the same wording, different deductibles, benefit limits, underwriting screens, administration services, endorsements and distribution chains. The reviewed population must identify the versions in force and those being offered, including any package of associated products and financing services.

A product inventory should therefore distinguish legal carrier, jurisdiction, product identifier, version, sale dates, eligibility conditions, benefit and exclusion structure, intended population, distributor, renewal rights and operational dependencies. The inventory establishes which contracts could be affected by a change and which systems must implement it. It also allows a historical review to reconstruct the conditions prevailing when a customer purchased cover.

Market segmentation is important to the integrity of that inventory. Different channels may offer the same insurance wording at different total prices or with different sales support. One channel's results may dominate the aggregate and conceal harm elsewhere. At the same time, segmenting almost every customer into a separate cell makes the analysis unstable. Product governance needs a justified level of aggregation: enough separation to expose economically or legally meaningful differences and enough observations to evaluate outcomes with reasonable credibility.

The legal basis of lifecycle review

Article 25 of the Insurance Distribution Directive (European Parliament and Council, 2016) establishes the European product approval and review architecture. Its scope includes an exception for insurance of large risks. Within the covered field, product governance is an organizational duty linked to the target market and intended distribution strategy; individual sales duties have their own legal basis.

The European Commission's (2017) Delegated Regulation 2017/2358 gives operational content to this architecture. Articles 3 and 4 identify the manufacturing role and the written approval process. Article 7 connects ongoing observation with regular review: review frequency reflects product characteristics, contract length, distribution and external changes. Where lifetime circumstances may adversely affect customers, manufacturers must act appropriately and communicate remedies to affected distributors and customers. Article 8 adds distribution monitoring. The allocation of manufacturing responsibility is especially important where an intermediary designs essential features and the insurer supplies the risk capacity.

At the international level, the IAIS (2024) ICP 19.5 framework permits supervisory approaches based on approval, principles or a combination and emphasizes customer interests in development and distribution. These standards guide supervisory systems; the duties enforceable against a particular insurer depend on the relevant domestic implementation. An insurer operating in several countries therefore needs a common analysis of product performance accompanied by a jurisdiction-specific map of legal decisions, deadlines and responsible persons.

The temporal structure of approval

Initial product approval is a forward-looking judgment using available evidence. Monitoring examines whether actual conditions remain consistent with the judgment. A scheduled review consolidates that evidence at a defined point, whereas event-driven review changes the timetable when a material assumption is challenged. These functions need separate ownership even when the same committee makes the final decision.

A scheduled review should consider changes in customer composition, contractual benefits, inflation, claims experience, underwriting results, sales incentives, cost structure, distributor performance and legal requirements as relevant to the product. Long-duration products require attention to assumptions extending beyond the next renewal. Short-duration covers sold at enormous volumes may demand rapid monitoring because substantial exposure can accumulate in a few days.

A review date is a deadline for completing a decision, not a reason to postpone recognition of an emerging problem. Internal policies can prescribe periodic intervals, but the underlying risk changes continuously. Governance must define who monitors between meetings, how anomalies reach the accountable function and who has authority to intervene before ordinary approval procedures conclude.

The role of product value

For UK non-investment insurance within scope, the FCA's (2026a) PROD 4.2 fair-value provisions require assessment of value including a reasonably foreseeable period after renewal. Product packages and the effects of distribution are part of the enquiry where the relevant provisions apply. Inability to identify and demonstrate fair value has consequences for continued marketing or distribution unless appropriate changes have been ensured. The evidentiary expectation is therefore stronger than completion of an annual form.

Value is an assessment of the relationship between payments and expected benefits under the relevant rule and product conditions. A useful review examines the price charged, accessibility and adequacy of protection, coverage restrictions, customer service, the cost and quality of distribution, and the actual experiences of relevant cohorts. Commercial viability remains important because an insurer must ultimately fund its promises. But profitability measures a different relationship from customer value. A manufacturer can be profitable while its customers receive weak or inaccessible protection; it can also be loss-making while delivering meaningful benefits.

Monitoring metrics and review triggers

A decision-oriented monitoring system

A monitoring system requires a defined observation, an appropriate denominator, a baseline, a review criterion and a named owner. The baseline may be the approved product assumptions, comparable versions, a historical distribution or an externally comparable dataset. These baselines answer different questions and should be recorded rather than silently substituted for one another.

Product-level information should combine financial experience with contractual and operational evidence. Claims counts, amounts and durations describe how the promise is realized. Sales composition, out-of-target sales, lapse and cancellation describe who buys and remains covered. Complaints, refusals, abandoned claims and service failures reveal obstacles to obtaining the promised benefit. Pricing and commission data identify potential changes in the allocation of customer payment. Legal and technology events can alter the validity of the entire proposition without immediately producing a statistical signal.

FCA (2026c) 2025 value measures data illustrate the relevant classes of claims measures and the significance of reporting corrections. Publicly reported bands and aggregates are useful screening inputs. They cannot independently reconstruct an individual product version or establish the cause of a divergence.

Denominators, timing and interpretation

For an internal cohort analysis, let E be earned policy-years of exposure and N the count of covered events assigned to that cohort under a consistent definition. Claim frequency is N/E. If X is the estimated ultimate cost of those claims, X/E expresses claim cost per unit of exposure. If P is matched earned premium, X/P is an incurred loss ratio for that defined population. Ultimate costs must distinguish paid sums, outstanding estimates and provisions for unreported claims where applicable. Inflation, recoveries, expenses and reinsurance treatment must be stated consistently.

These definitions serve analytical purposes and are distinct from jurisdiction-specific reporting formulas. FCA (2026d) SUP 16.27 reporting definitions use registered claims and average policies in force for frequency and exclude certain claim types from the registered denominator. The reporting denominator is valuable for regulatory comparability but cannot be used indiscriminately for an internal funnel analysis. The analyst should retain the original event-level categories, especially abandonment and rejected contacts, when investigating access to coverage.

A deterioration in a paid-claims-to-written-premium measure may reflect increased premiums, growth, lagged claims payment or changes in portfolio mix. The FCA (2024d) 2023 value measures commentary explicitly discusses timing in motor insurance experience. A review should compare mature cohorts, reconcile development periods and isolate the effects of changes in exposure and pricing rather than drawing conclusions from a calendar-period quotient alone.

The same discipline applies to complaints. A rate per thousand policies answers how commonly policyholders complain; a rate per thousand claimants answers how frequently a complaint occurs among those attempting to use cover. A product may have few complaints per policy because claims are rare, yet have severe problems among claimants. Counts and severity categories must remain available alongside ratios. Products with exceptionally low claim frequency require qualitative testing because a small number of claims cannot establish the quality of a complex service process.

A worked segmentation example

Consider a hypothetical annual product with two channels. Channel A has 9,000 covered policy-years and 450 registered claims; 405 claims are accepted. Channel B has 1,000 policy-years and 50 registered claims; 30 are accepted. Using the simplified assumption that every claim is classified in the same period and no observations are excluded, frequency is 5% in both channels. Acceptance is 90% for A and 60% for B; the combined rate is 435/500, or 87%.

The aggregate rate exceeds many plausible internal warning levels but hides a 30-percentage-point channel difference. That difference could arise from eligibility failure, customer misunderstanding, distribution misalignment, differences in event composition or the application of policy terms. The review first checks that coding and cohorts are comparable. It then examines representative accepted, denied and abandoned files, sales records and wording. A targeted pause is justified if evidence indicates ongoing serious preventable harm and the relevant authority permits it. A final conclusion about redress requires assessment of the actual defect and affected population.

If the sample is treated only for illustration as independent Bernoulli observations, the approximate standard error of the difference is the square root of 0.9 times 0.1 divided by 450 plus 0.6 times 0.4 divided by 50, approximately 0.071. The observed difference is large relative to that sampling error. Real claims may be clustered by seller, event or claims handler; the sample may also be selected by customer behavior. Consequently this calculation supports prioritization of investigation, not a causal finding or a binding legal threshold.

Trigger design and uncertainty

A trigger can take the form of a predetermined quantitative threshold, a sustained departure from expectation, a significant individual event or a structural change. A single severe complaint asserting systematic exclusion of the intended market may warrant immediate review even when aggregate measures remain satisfactory. A material change in benefits, distributor incentives, claims infrastructure, legislation, underwriting or reinsurance capacity may require consideration before a deterioration appears in outcome data.

Thresholds should be justified by the product and the consequences of error. Under a stable distribution a warning level may be selected using historical variance or an actuarial predictive interval. A higher-frequency indicator can use short observation windows; rare losses require longer windows and event intelligence. Monitoring many segments increases the frequency of chance anomalies, while excessive statistical correction can delay detection of serious harm. The organization needs a documented response to uncertainty rather than a mechanical rule that treats every alert equally.

Risk preferences and customer circumstances are heterogeneous. Cohen and Einav (2007), in their study of deductible choice, use automobile insurance choices to estimate underlying preference heterogeneity. Their abstract-level finding supports caution against interpreting a uniform contract feature as having identical value for every purchaser. It does not establish any universal insurance value threshold.

An internal warning need not constitute a breach of law. Conversely, absence of a numerical warning does not prove compliance. A legal trigger can have a mandatory consequence independently of statistical confidence. Australia provides a particularly instructive distinction because the Corporations Act 2001 binds covered target market determinations to specified review events and distribution restrictions. An issuer must maintain a separate calendar of applicable statutory duties and escalation procedures.

Independent evaluation and escalation

From signal to accountable decision

Monitoring is meaningful only when a signal moves into a recorded investigation with an owner and decision time. The first stage should preserve the observation, identify the affected product and version, establish the time of discovery, determine the likely customer consequences and identify immediate legal duties. The assignment should not be suspended simply because a complete causal explanation is unavailable.

An independent evaluation requires separation between the functions whose decisions are assessed and those responsible for challenging the assessment. Product and actuarial teams have essential technical knowledge. Claims and distribution teams supply implementation evidence. Legal and compliance specialists establish the relevant obligations. Risk management tests assumptions and aggregations and internal audit may evaluate the design and functioning of governance controls. The precise arrangement depends on institutional scale and applicable law; a small firm may use independent individuals or external expertise rather than duplicate departments.

The reviewer should be authorized to inspect adverse evidence and escalate disagreement. A business owner with a revenue target may reasonably prefer to avoid unnecessary suspension; that perspective is legitimate but cannot control the evaluation of customer harm. An escalation record should preserve dissents, competing options, the decision authority and the reasons why alternatives were rejected.

Materiality and urgency

Materiality reflects the number of potentially affected customers, severity and persistence of possible harm, the probability that harm continues, the vulnerability and dependency of affected populations, and the reversibility of the outcome. An exclusion that defeats the primary reason consumers buy a product may be material even if very few consumers have yet claimed. An anomaly causing a small overcharge to a large population may likewise be material because the harm accumulates and can affect confidence in the institution.

The relevant distinction is between sufficient evidence for intervention and sufficient evidence for final causation or redress. A temporary restriction may be protective under uncertainty. It must be proportionate, legally available and accompanied by investigation. An organization should record which evidence is known, which claims remain contested, which interim measures are applied and what evidence will resolve the decision.

A practical escalation record can contain the initial observation, source and version of data, time of awareness, applicability of legal triggers, initial severity assessment, affected and potentially affected contracts, immediate protective action, investigation owner, authority, notification requirements, decision deadline and review date for the interim control. Records must permit reconstruction of what was known at each decision point.

Supervisory evidence and organizational failure

The FCA's (2024c) TR24/2 thematic review examined information from 28 manufacturers and 39 distributors across 10 products. Its official summary identifies deficiencies in manufacturers' demonstration of fair value and distributors' understanding of remuneration-related value impacts. These findings are evidence of observed supervisory concerns within the review. They do not yield the incidence of failure throughout all insurance markets.

The organizational lesson is that the chain of responsibility must include a feedback path. A distributor that receives recurring complaints about eligibility should report the issue to the manufacturer; the manufacturer should connect those complaints to the approved target market and consider whether distribution remains suitable. Information sharing needs clear definitions, periodicity and escalation deadlines. Outsourced functions should receive the same version-controlled instructions and should return evidence of actual implementation.

EIOPA's (2026) POG peer review follow-up reports increased maturity of supervision since the earlier peer review, including shifts toward more operational and product-focused approaches. The summary supports a direction of supervisory development, not a quantified reduction in customer harm. It also reinforces the distinction between a documented process and an operational assessment backed by evidence.

Product modification and customer remedy

Matching the corrective action to the identified defect

Corrective action should address the relation that has failed. If distribution creates the problem, channel restrictions, altered incentives, improved eligibility screens, staff training or a revised disclosure may be warranted. If the design creates the problem, change in exclusions, benefits, deductible, duration or coverage wording may be necessary. If the cost structure is incompatible with fair value, changes to premiums, commissions, financing costs or package structure may be appropriate. If individual customers have suffered loss because of a defect, a separate remediation process must determine the appropriate remedy.

These interventions can be combined but should remain analytically distinct. A reduction in commission may improve future value without compensating existing affected customers. Expanded future coverage may not address claims incorrectly declined under previous terms. A clearer disclosure may improve understanding but cannot make a substantively unsuitable product suitable. The action must identify the mechanism responsible for harm and the population to which it applies.

A modification also needs an assessment of the new risk. Lowering premiums without examining expected claim obligations and expenses may undermine the carrier's ability to maintain protection. Expanding benefits without evaluating reserves, underwriting and reinsurance can create prudential exposure. Restricting sales to an apparently appropriate group can change pool composition and affect future affordability. Corrective action therefore involves actuarial and financial reassessment in parallel with the conduct assessment.

Repricing and economic incidence

Consider an illustrative annual premium of 200 monetary units, of which expected claim cost is 90, operating cost 35, distribution cost 45 and the remaining 30 pays for residual risk and profit. Suppose review establishes that the distribution cost is excessive relative to its service. A reduction of distribution cost from 45 to 25, passed through in full, reduces the premium to 180 and changes expected claim cost relative to premium from 45% to 50%. The 20-unit reduction may improve customer value while preserving the same modeled residual.

That conclusion depends on unchanged exposure, benefits, demand, expenses and risk assumptions. If the new price attracts materially different risks, expected claims may increase. If commission reduction eliminates useful assistance, the improvement in price may coincide with lower service quality. If contract costs are partly fixed, a change in volumes may alter the residual. The numerical exercise is a reconciliation of a hypothesized cost allocation, not an actuarial pricing recommendation or statutory fair-value test.

The governing decision should distinguish reductions in future premium from refunds or other remedies for prior customers. The latter require a defensible connection to actual entitlement, causation and applicable law. A past high price by itself does not establish a legal entitlement to repayment. Similarly, a later redesign does not by itself prove that all earlier sales were unlawful.

Remediation populations and evidence

A remediation program must identify the affected policy versions, distribution channels, relevant sale and claim dates, the defect, the possible consequences and applicable rights. It should use customer-level evidence where available and transparent, justified proxies where records are incomplete. Affected persons may include former policyholders, beneficiaries and individuals who abandoned or were discouraged from making a claim.

The remedy could involve a corrected claim decision, payment of contractual benefits, restoration of cover, revised terms agreed where necessary, reimbursement, cancellation assistance or another legally appropriate solution. The firm should avoid requiring customers to prove matters already established in its records. Communications must make the purpose, available options, relevant dates and complaints routes intelligible.

Implementation should be checked independently. For example, the reviewer can reconcile the affected cohort count against notices sent, payments completed and unresolved exceptions; test that the changed product appears consistently across distributors; and monitor reopened cases. A remediation plan is not complete merely because a payment instruction has been approved. Its implementation and residual risk need evidence.

Significant modifications and reassessment

The product approval process may apply again when existing products are significantly adapted. Material changes to contract terms, eligibility, customer segment or distribution should be assessed against the applicable definition in the relevant jurisdiction rather than treated automatically as minor maintenance. The reviewer should retain the relationship between old and new versions and avoid overwriting the evidence supporting former decisions.

The FCA (2026b) Consumer Duty provisions also illustrate how scope, existing and closed products, specific product governance regimes and rights under older contracts can interact. The applicable rule must be identified before designing a remedy. In particular, the Consumer Duty contains specific application and vested-rights provisions; a review cannot assume that contractual rights may be unilaterally rewritten.

Suspension, exit and legacy policy obligations

Distinguishing restriction, withdrawal and contract cessation

A suspension is a reversible restriction on defined future activities while evidence is examined or corrective action is implemented. A withdrawal ends the availability of a product or line on specified terms. Closing new sales can leave renewals available; closing renewals can leave policies in force until expiry; cancellation before expiry raises separate contractual and legal issues. A product's marketing state must never be used as a substitute for its contract state.

Withdrawal also differs from insurer insolvency. A solvent insurer may close an unprofitable product and administer its remaining liabilities for many years. An insolvent insurer may be subject to resolution, receivership or other statutory proceedings regardless of the merits of individual products. The consequences of withdrawal depend on the carrier, the contract and the territorial regime.

Operational instructions should specify the affected product versions, channels, jurisdictions, new business, pending proposals, renewals, endorsements, contractual exercises of options and claims and servicing activities. An indiscriminate switch-off may prevent customers from making valid claims, receiving policy documents or exercising existing options. A sales control must target the activity it is intended to restrict.

Documented intervention and restart

On February 9, 2024, the FCA announced the GAP sales pause after several firms agreed to suspend selling guaranteed asset protection insurance following its request. The firms represented 80% of the market according to the announcement. The action concerned customer value and demonstrates that distribution can be temporarily restricted without treating an entire insurance category as incapable of serving a useful function.

On May 24, 2024, the FCA announced permitted GAP recommencement for several firms after its intervention. Its statement tied restart to demonstrating fair value and emphasized the point-in-time character of the assessment. These two official announcements establish the administrative sequence; they do not establish the amount of customer harm avoided or the ultimate value of each redesigned policy.

The Australian regulator's (2023) pet insurance stop-order announcement offers a different example. ASIC issued 38 interim orders concerning 67 products, restricting retail distribution to new customers because target market determinations inadequately addressed consumers' financial circumstances and their ability to pay veterinary costs before reimbursement. The regulator reported amendments addressing its concerns and revocation of the orders on June 29, 2023, without final orders. The case illustrates how a restriction can permit targeted revision and renewed distribution; it does not establish a completed assessment of every affected contract or the absence of residual harm.

For an insurer contemplating restart, the analysis suggests a clear closure test: the original defect should be identified to the extent necessary for control, changes implemented, new distribution instructions confirmed, relevant legal conditions satisfied and initial outcomes monitored after reopening. A future review can test whether the correction has persisted. An unresolved historical compensation program should remain visible even if the conditions for future sales have been met.

Statutory restrictions on product distribution

Australian design and distribution law provides an example of a legal stop rule linked to knowledge of an event. Under the inspected September 2026 compilation, section 994C(3)-(4) of the Corporations Act imposes restrictions on the maker of a covered target market determination when the specified conditions occur, subject to the review/new determination and excluded-conduct alternatives. The outside limit is ten business days after first knowledge, with action required earlier when practicable. Section 994F separately provides reporting obligations for covered distribution. These provisions are specific to their statutory conditions; they are not permission to continue activity for ten days irrespective of circumstances.

The distinction has consequences for governance: a metric that crosses an internally selected warning level may trigger an inquiry without a statutory stop, whereas an event within the statutory rule can require restriction notwithstanding uncertainty about the ultimate cause. The firm must record the knowledge date and determine which activities constitute regulated distribution in each case. A blanket global rule could either omit mandatory local action or restrict lawful servicing.

Territory and line withdrawal

United States legal requirements are state- and line-specific. Texas Insurance Code Chapter 827, section 827.003, requires a withdrawal plan for specified proposed reductions: 50% or more of total annual premium volume, 75% or more in a line, or 50% or more in a personal automobile or residential property line statewide or within an applicable rating territory. Section 827.004 requires provision for contractual obligations, service to policyholders and claimants, and applicable statutory obligations. Sections 827.005 and 827.008 distinguish withdrawal review from certain restrictions in new business following a catastrophic event. The Texas Department of Insurance (n.d.) Withdrawal Guidelines explain the administrative process, including prior approval before notices where required. The applicable statutory definitions, exceptions, and implementing procedures determine the precise legal consequences.

This regime addresses the consequences of exit for consumers and markets. A withdrawal may remove risk capacity from a region where substitutes are scarce. A product-level sales decision and a regulated withdrawal from a line of business are analytically separate, even if a single commercial decision eventually engages both. Section 827.005 allows modification, restriction or limitation of a plan under specified market-availability conditions. Exit governance therefore requires consideration of both contractual continuity and the availability of protection. This comparative account focuses on the cited statutory provisions and agency guidance rather than an exhaustive audit of Texas insurance law.

A withdrawal plan should assess concentrations of affected contracts, plausible replacement availability, mandatory coverage requirements, timing, notices, claims and outstanding liabilities, and the resources to operate the run-off. The precise legal contents and submission procedure must be confirmed before implementation. The legal authority to stop new business does not automatically authorize a policy transfer or early termination.

Governing the closed portfolio

A closed book may contain long-duration guarantees, claims arising after closure, renewals or options subject to particular contract rights, unresolved disputes and customers who cannot obtain comparable protection elsewhere. Maintaining access to valid benefits requires administration infrastructure, data retention, sufficient financial provision, trained staff, claims handling and effective communications.

Consider a life or health product that is closed to new customers. Replacement may require medical underwriting at an older age, exclude preexisting conditions or reset waiting periods. A lower premium for a replacement policy may therefore conceal a substantial loss of insurance value. A migration decision must compare actual rights and eligibility rather than price alone. Customers should not be pressured to exchange valuable existing rights for ostensibly similar new cover.

The FCA Consumer Duty's treatment of existing and closed business illustrates why stopping marketing does not exhaust the governance enquiry. Applicable obligations continue in accordance with the product and activity scope, while specific protections for vested rights constrain certain remedies. The Texas guidance likewise ties cancellation of an insurer's certificate of authority to the settlement of remaining policyholder obligations. These examples arise from different legal structures but identify the enduring problem of promises after exit.

An accountable run-off plan should monitor claims duration, retained service levels, unresolved complaints, capital and reserve requirements, technology continuity and contractual delegated arrangements. Where administration migrates to another supplier or books are transferred, mapping of obligations and legal approvals must be preserved. Closure is an ongoing operating condition, not simply a status assigned by a product committee.

Cross-jurisdiction review and governance synthesis

Comparing mechanisms and legal force

The comparison identifies several distinct mechanisms. The EU framework applies lifecycle product governance to covered insurance manufacturing and distribution. UK rules add a particular fair-value dimension for covered non-investment insurance and interact with the Consumer Duty according to scope. Australia centers defined design and distribution duties on target market determinations and specifies event-related constraints. Texas illustrates state oversight of material withdrawal from relevant lines and markets. The IAIS provides an international supervisory reference that accommodates different domestic approaches.

Jurisdiction or framework Main object of the reviewed mechanism Illustrative consequence
European Union Product and target market; distribution strategy Ongoing reassessment and appropriate corrective action
United Kingdom Covered insurance product and fair-value assessment Distribution restriction or effective modification where value cannot be evidenced
Australia Covered target market determination Event-related distribution restrictions and review
Texas Applicable line or market withdrawal Prior plan approval and continuing obligations where required
IAIS Domestic supervisory framework Customer-interest expectations through approval or principles-based approaches

The comparison is functional, not a claim that these jurisdictions have identical legal duties. A multinational insurer can use a centralized monitoring process while retaining a legal map of local triggers, permissions, notifications and customer rights. An action accepted in one jurisdiction may require an approval or different timing in another. The appropriate control is a common inventory of observable problems followed by country- and product-specific legal assessment.

Analytical implications for continued availability

Continued availability is defensible when the premise of the product remains supported, applicable duties are met and residual risks are controlled. Where a material assumption fails, the relevant decision is which corrective action can protect customers and preserve legitimate contractual and financial interests. A minor and readily reversible design or communication failure may warrant a targeted correction. A serious persistent failure may justify broader restriction or withdrawal. This is an interpretation of the evidence and governance problem, not a proposed new legal doctrine.

When evidence is inconclusive, the cost of gathering further information must be considered alongside the consequences of continued sales. Delay can create avoidable exposure, especially in high-volume distribution. Immediate withdrawal can also harm customers if alternatives are unavailable or coverage is compulsory. The selection of interim controls depends on reversibility, the severity of plausible harm and applicable law.

The review should test alternatives under an explicit counterfactual: what happens if sales continue unchanged, if they continue under a revised restriction, if they are suspended temporarily, or if the proposition is permanently withdrawn? The options affect prospective customers, existing customers, the institution's solvency and the availability of protection in different ways. A good decision record makes these consequences visible and describes the uncertainty around them.

A worked lifecycle decision

Assume a hypothetical travel cover sold online has continued to show an acceptable portfolio loss ratio. A change in automated eligibility screening has nevertheless allowed sales to a substantial group whose primary planned activity is excluded by the wording. Complaints remain few because many customers have not yet traveled. The mismatch is discovered by a distributor reviewing customer records.

The manufacturer should first preserve the version of the sales process and contract, establish when the screening change began, identify potentially affected customers and determine whether continued distribution is lawful. In a jurisdiction with a mandatory event-linked stop, that requirement takes priority. Elsewhere a targeted channel restriction pending investigation may be appropriate. Claims service and valid existing rights should remain available.

The subsequent investigation tests the eligibility condition against actual sales records, reviews accepted and rejected claims and determines whether other channels were affected. Possible corrective actions include restoring screening, aligning contract terms with the intended market, revising sales language and considering remedies for affected customers. The correct option depends on what coverage was promised, the applicable sale duties and the nature of consumer loss. An improvement in the average portfolio loss ratio is irrelevant if the mismatch remains.

The final decision record should describe the original defect, affected period and customer population, remedial treatment, version-specific controls and evidence supporting any restart. Follow-up monitoring should test whether the change has materially reduced out-of-target sales and whether customers understand and can use their protection. This example demonstrates the connection between prospective correction, historical remedy and residual operational responsibility.

Limits of the evidence and future research

The present study compares selected public legal and supervisory materials. It does not provide a complete survey of national insurance laws, a causal assessment of supervisory interventions, a current filing guide, a calibrated decision threshold or an evaluation of a named product's value. Report summaries and abstracts support only claims contained in those materials. The use of regulator announcements introduces selection effects: highly visible interventions may be unlike routine successful reviews.

Future empirical work could use matched product-version and claims cohorts, date-stamped distribution changes, documented review triggers and control-group comparisons where ethical and feasible. It should distinguish the decision to intervene from its effects and account for concurrent pricing, market and regulatory changes. Prospective measures might include out-of-target sales, claim resolution and access, customer retention with appropriate cover, and replacement outcomes after withdrawal. Data access, privacy, exposure maturity and selection bias would determine whether such estimates are credible.

The scientific contribution of this monograph is the explicit comparative and analytical connection among trigger design, independent escalation, prospective restriction, historical remedy and enduring policy obligations. The evidence supports that synthesis without establishing a new theory or claiming priority over earlier scholarship.

Conclusion

Insurance product approval remains credible through a review process that tests the assumptions underlying the product across its life. Scheduled and event-triggered reviews perform complementary functions. Quantitative indicators identify changes that warrant attention; qualitative evidence identifies failures that aggregate experience may conceal. A signal initiates enquiry and may justify interim protection; the choice of final corrective action requires a reasoned assessment of the defect and affected population.

Independent evaluation connects monitoring to accountable decisions. It enables the manufacturer to distinguish distribution failure, contractual design problems, pricing or cost issues and deficiencies in customer support. Corrective repricing, redesign and channel restrictions address different mechanisms and require corresponding verification. Remediation of past harm remains a separate question from improving the future proposition.

Withdrawal governance extends these responsibilities into the closed portfolio. A decision to suspend new sales, close renewals or leave a market must separately preserve lawful contract performance and take account of consumer reliance and protection availability. The continuing administration of valid promises remains a fundamental component of insurance governance.

The selected legal frameworks use different mechanisms for this common institutional task. Their differences matter for practical decision-making, particularly where deadlines, restrictions or regulatory approvals apply. The strongest conclusion is that product review is effective only when observation, timely decision, implemented correction and continuing responsibility form a traceable institutional process.

References

  • Australian Securities and Investments Commission. (2023). 23-174MR ASIC issues 38 DDO stop orders for pet insurance products. Media release, 29 June 2023. Pet insurance stop orders

  • Cohen, A., & Einav, L. (2007). Estimating Risk Preferences from Deductible Choice. American Economic Review, 97(3), 745-788. DOI: 10.1257/aer.97.3.745. Cohen and Einav

  • Commonwealth of Australia. (2001). Corporations Act 2001 (Cth), Part 7.8A, ss. 994B-994G and 994J. Compilation in force 19 September 2026, volume 4. Federal Register of Legislation. Corporations Act Part 7.8A

  • European Commission. (2017). Commission Delegated Regulation (EU) 2017/2358 of 21 September 2017 supplementing Directive (EU) 2016/97 with regard to product oversight and governance requirements. Official Journal L 341, 1-7. Consolidated text, 2 August 2022. Delegated Regulation 2017/2358

  • European Insurance and Occupational Pensions Authority. (2026). Follow-up Report to EIOPA's Peer Review on Product Oversight and Governance (POG). EIOPA-BoS-26-249, 30 June 2026. Publication summary. POG peer review follow-up

  • European Parliament and Council. (2016). Directive (EU) 2016/97 of 20 January 2016 on insurance distribution, Article 25. Official Journal L 26, 19-59. EIOPA rulebook reproduction. IDD Article 25

  • Financial Conduct Authority. (2024a). GAP insurers agree to suspend sales following FCA concerns over fair value. Press release, 9 February 2024. GAP sales pause

  • Financial Conduct Authority. (2024b). Firms to recommence GAP insurance sales following FCA action. Press release, 24 May 2024. GAP sales recommencement

  • Financial Conduct Authority. (2024c). TR24/2: General insurance and pure protection product governance thematic review. 21 August 2024; landing page updated 3 December 2025. TR24/2 thematic review

  • Financial Conduct Authority. (2024d). General insurance value measures data 2023. FCA data publication, reporting year 2023. 2023 value measures

  • Financial Conduct Authority. (2026a). FCA Handbook, PROD 4.2: Manufacture of insurance products. Online rulebook, including rules effective 26 June 2026. PROD 4.2

  • Financial Conduct Authority. (2026b). FCA Handbook, PRIN 2A: The Consumer Duty. Online rulebook, including provisions effective 26 June 2026. PRIN 2A

  • Financial Conduct Authority. (2026c). General insurance value measures data 2025. FCA data publication, reporting year 2025. 2025 value measures

  • Financial Conduct Authority. (2026d). FCA Handbook, SUP 16.27: General insurance value measures reporting. Online rulebook. SUP 16.27

  • International Association of Insurance Supervisors. (2024). Insurance Core Principles and Common Framework for the Supervision of Internationally Active Insurance Groups. Online tool, ICP 19.5 and guidance 19.5.1-19.5.5. ICP 19.5

  • Marano, P. (2021). The Contribution of Product Oversight and Governance (POG) to the Single Market: A Set of Organisational Rules for Business Conduct. In P. Marano & K. Noussia (Eds.), Insurance Distribution Directive. AIDA Europe Research Series on Insurance Law and Regulation, vol. 3. Springer, Cham, pp. 55-74. DOI: 10.1007/978-3-030-52738-9_3. Marano chapter

  • State of Texas. (n.d.). Texas Insurance Code, Title 6, Subtitle B, Chapter 827: Withdrawal and Restriction Plans, secs. 827.003-827.005 and 827.008. Official statutory text. Texas Insurance Code Chapter 827

  • Texas Department of Insurance. (n.d.). Withdrawal Guidelines. Financial Regulation Division, online guidance. Withdrawal Guidelines